New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 19, 2014
13:00 EDTNKTRNektar presents data from Phase l study of etirinotecan pegol
Nektar presented favorable data today from a Phase 1 study of etirinotecan pegol, EP, NKTR-102, in combination with 5-fluorouracil, 5-FU/Leucovorin LV, in patients with advanced cancer. NKTR-102 is the first long-acting topoisomerase I-inhibitor designed to concentrate in tumor tissue, provide sustained tumor suppression throughout the entire chemotherapy cycle, and to reduce the peak exposures that are associated with toxicities of other cytotoxics. These new data were presented at the 2014 Gastrointestinal Cancers Symposium in San Francisco.
News For NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 26, 2014
07:31 EDTNKTRNektar announces MOVENTIG receives positive CHMP opinion in EU
Subscribe for More Information
September 24, 2014
10:35 EDTNKTRHigh option volume stocks
Subscribe for More Information
September 19, 2014
09:01 EDTNKTRNektar presents preclinical data on kappa opioid receptor
Nektar announced results from preclinical studies characterizing the analgesic profiles of a series of the company's internally-discovered oral, peripherally-acting kappa opioid receptor agonist molecules. The analgesic properties of kappa receptor agonism are well described in the medical literature.1,2 Kappa opioid receptors are expressed in the peripheral nervous system as well as in the central nervous system, and activation of these receptors at both sites has been shown to result in a reduction in pain and inflammation in a wide range of preclinical models. However, the therapeutic use of kappa receptor agonists has been limited because activation of these receptors in the CNS is associated with significant dysphoria and other unwanted side effects.
September 17, 2014
08:50 EDTNKTRNektar Movantik approval positive, says Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use